Table 4.

Summary of models evaluating the effect of covariates on the pharmacokinetic parameters of indinavir

		Run model	Objective function value	DOFa
1	Base model		2963	–
Intermediate model
CL/F
2	with and without ritonavir*	θ1 × RTV + (1 − RTV) θ6	2940	22
3	MDR1 3435C>T	θ1 × 3435CC + θ6 × 3435CT + θ7 × 3435TT	2956	7
4	MDR1 2677G>T	θ1 × 2677GG + θ6 × 2677GT + θ7 × 2677TT	2962	1
5	CYP3A5 *1/*3 (6986A>G)	θ1 × 6986AG + θ6 × 6986GG	2962	1
6	CYP3A5 27050A>G	θ1 × 27050AA + θ6 × 27050AG	2963	0
7	CYP3A5 31611C>T	θ1 × 31611CC + θ6 × 31611CT	2962	1
ka
8	MDR1 3435C>T	θ3 × 3435CC + θ6 × 3435CT + θ7 × 3435TT	2945	17
9	MDR1 2677G>T	θ3 × 2677GG + θ6 × 2677GT + θ7 × 2677TT	2957	5
10	CYP3A5 *1/*3 (6986A>G)	θ3 × 6986AG + θ6 × 6986GG	2962	1
11	CYP3A5 27050A>G	θ3 × 27050AA + θ6 × 27050AG	2963	0
12	CYP3A5 31611C>T	θ3 × 31611CC + θ6 × 31611CT	2960	3
V/F
13	MDR1 3435C>T	θ2 × 3435CC + θ6 × 3435CT + θ7 × 3435TT	2962	1
14	MDR1 2677G>T	θ2 × 2677GG + θ6 × 2677GT + θ7 × 2677TT	2962	0
15	CYP3A5 *1/*3 (6986A>G)	θ2 × 6986AG + θ6 × 6986GG	2962	1
16	CYP3A5 27050A>G	θ2 × 27050AA + θ6 × 27050AG	2958	5
17	CYP3A5 31611C>T	θ2 × 31611CC + θ6 × 31611CT	2962	0
Final model
18	CL/F (RTV) and ka (MDR-1 3435)		2927	14**

^adecrease of objective function

^*best intermediate model

^**DOF from best intermediate model; CL/F clearance; V/F volume of distribution; k_a,rate of absorption constant.